Acurox(TM) Tablets Significantly Disliked When Excess Doses are Swallowed PALATINE, IL, and BRISTOL, TN, USA | October 13, 2008 | Acura Pharmaceuticals, Inc. (NasdaqCM:ACUR - News) and King Pharmaceuticals, Inc. (NYSE:KG - News) today announced top-line results from Study AP-ADF-111 (Study 111) entitled ``A Phase II, Single-Center, Randomized, Double-Blind, Assessment of the Abuse Liability of Acurox(tm) (oxycodone HCl and niacin) Tablets in Subjects with a History of Opioid Abuse.'' Study 111 results demonstrate that Acurox(tm) Tablets are disliked compared to oxycodone HCl tablets alone when excess doses are swallowed. These results are statistically significant based on the dislike/like scores (p = .033), the primary measure of abuse deterrence potential for the study. Acurox(tm) Tablets contain a unique composition of...
[read full story]
Your Web Site
